Jymed Fasaha Co., Ltd. ya yi farin cikin sanar da cewa samfurinsa, ya yi nasarar kammala rajista na Master (DMF) tare da FDA ta Amurka (lambar DMF) tare da FDA ta Amurka (lambar DMF) tare da FDA ta Amurka (lambar DMF) a ranar 2 ga watan Agusta, 2024.
Mass samar da ingancin inganci
A cewar manyan ayyukan Jymed na Jymed, babban samarwa na Tirzeptade Sinadaran pharmaceticical (API) na iya kaiwa matakan kilogram. Barken samarwa yana da tsayayye da ci gaba, tare da ƙarancin bambancin adadi tsakanin batura, yana tabbatar da ingancin inganci.
Muhimman sakamako akan glucose da rage lipid
Tirzepatitide shine farkon farko a duniya da mako daya gip / murnar murjani 1. A matsayina na wani mai rikitarwa na biyu mai karba, zai iya yin kwalliya a lokaci guda kuma kunna duka polypeptip na glcose (Gip) mai karbar kudi da kuma mai karbar hoto a jikin mutum. Baya ga rage matakan glucose, yana rage yawan abinci, nauyin jiki, da mai, kuma yana tsara amfani da lipid. Bayan babban glucose da karancin nauyi-ruguye-results, nazarin subgroup daga jerin karatuttukan jini kamar tirzeptap na jini, bmids na jini, BMI, da karkara.
Yarjejeniyar da yawa da kuma siyan masu sahihanci
A cewar bayanin da ya dace, an fara samar da kasuwar Glucise ta FDA a 20222 don maganin manya da ke da ciwon sukari na 2. Daga baya ya sami amincewa a cikin EU, Japan, da sauran yankuna. A Nuwamba 2023, FDA kuma ta amince da asarar asarar asarar nauyi a ƙarƙashin sunan sunan Zephbound. A watan Mayu 2024, ya samu nasarar shiga kasuwar kasar Sin. Bayar da babban burin aikace-aikace da karfi tallafawa bayanan bincike, Tirzeptide ya zama ɗayan manyan magungunan peptide a yau. Kayayyakinta ya kai dala biliyan 5.163 a cikin 2023, da farkon kwata na 2024 kadai ya ga tallace-tallace na $ 2.324 na biliyan 2.324, nuna ingantaccen ci gaban girma.
Game da jymed
Shenzhen Jyed Fasaha Co., Ltd. (na daga nan eninfst an kafa shi a cikin 2009, ƙwarewa a cikin binciken, ci gaba, samarwa, da kuma sayar da abinci da kayayyakin peptide. Tare da cibiyar bincike guda ɗaya da manyan tushen masana'antu, joymed yana daya daga cikin manyan masu samar da kayan kwalliya na APPID APT a China. Kamfanin kamfanin Kamfanin na Kamfanin ya yi alfahari da shekaru 20 na gogewa a cikin masana'antar abinci kuma ya samu nasarar aiwatar da FDA sau biyu. Cikakken tsarin masana'antar jymed.
Babban ayyukan kasuwanci
1.Daga Rajistar cikin rajista na kasa da Apptide Apis
2. ACERE DA TAFIYA
3.Toustom peptides da Cro, CMO, OEM aiyukan
4.PDC kwayoyi (peptide-radionuclide, peptide-kananan kwayoyin, peptide-furotin, peptide-rna)
Baya ga Tirzeptade, Jymed ya gabatar da takardu tare da FDA da kuma cde don wasu magungunan API-1RA na yanzu kamar Semaglutide da Lira. Abokan ciniki masu zuwa na gaba suna amfani da samfuran Jymed nan gaba za su iya yin lambar lambar rajista ko lambar fayil ɗin DMF lokacin ƙaddamar da aikace-aikacen rajista zuwa FDA ko CDE. Wannan zai rage yawan da ake buƙata don shirya takaddun aikace-aikacen, da kuma lokacin kimantawa da farashin bita na samfurin.
Tuntube mu
Shenzhen Jyed Fasaha Co., Ltd.
Adireshin:8th & 9th bengers, gini 1, shenzhen biomita ce ta samar da masana'antu na biomitaPark, No. 14 Jinhuu Titin, Kengzi Subdistriclor, gundumar Ponsshan, Shenzhen
Waya:+86 755-26612112
Yanar gizo: http://www.jymech.com/
Lokaci: Aug-12-2024
